NeuroVive signs mitochondrial medicine research agreement with US key opinion leader

http://www.neurovive.com/en/press-releases/?y=2017

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

http://www.gensight-biologics.com/uploads/Modules/InvestorNews/gensight-biologics---pr---78-weeks-results_vfinal.pdf

United Kingdom gives green light for mitochondrial replacement technique

http://www.sciencemag.org/news/2016/12/uk-gives-green-light-mitochondrial-replacement-technique

Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical trial with KH176 in MELAS/MIDD and mixed mitochondrial syndromes

http://www.khondrion.com/News-detail/4053/38990/KHENERGY-completion-of-recruitment-and-first-in-patient-dosing.html?publicationdate=True

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide which will evaluate the long-term safety, tolerability and efficacy

http://www.stealthbt.com/stealth-biotherapeutics-initiates-phase-2-study-elamipretide-primary-mitochondrial-disease/

Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes

http://www.khondrion.com/News-detail/4053/36546/KH176-Phase-2-clinical-trial.html?publicationdate=True

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

http://www.gensight-biologics.com/uploads/Modules/InvestorNews/gensight-biologics_pr_paediatric-ind-gs010-phase-iii_08092016_vdef-2.pdf

Edison Pharmaceuticals Announces Positive Results from Phase 2 Placebo-Controlled EPI- 743 Leigh Syndrome Trial

http://edisonpharma.com/wp-content/uploads/160623_Edison-Pharmaceuticals-LS-Trial-Update.pdf

Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial

http://www.stealthbt.com/stealth-biotherapeutics-reports-positive-elamipretide-data-first-kind-primary-mitochondrial-myopathy-trial/

GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

http://www.gensight-biologics.com/uploads/Modules/InvestorNews/gensight-biologics-results-gs010.pdf

Stealth BioTherapeutics Reports Positive Results for Primary Mitochondrial Myopathy Trial

http://www.stealthbt.com/stealth-biotherapeutics-reports-positive-results-primary-mitochondrial-myopathy-trial/

Clinical Investigations of Mitochondrial Replacement Techniques Are ‘Ethically Permissible’ If Significant Conditions Are Met.

http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=21871

A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies.

http://www.ncbi.nlm.nih.gov/pubmed/26741492

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication.

http://www.stealthbt.com/stealth-biotherapeutics-receives-fda-fast-track-designation-for-rare-disease-indication/

Khondrion reports successful outcome of KH176 Phase 1 Clinical trials.

http://www.khondrion.com/News-detail/4053/30256/KH176-Phase-1-Clinical-trials.html?publicationdate=True

Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage.

http://www.ncbi.nlm.nih.gov/pubmed/26609120

Santhera launches Raxone® in its first EU market.

http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201510&newsid=1955888&newslang=en

GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010.

http://www.gensight-biologics.com/index.php?mact=News1,cntnt01,detail,0&cntnt01item_id=7&cntnt01title=GenSight%20Biologics%20Receives%20IND%20Acceptance%20from%20FDA%20to%20Enter%20Phase%20III%20with%20GS010&cntnt01returnid=37

Reata Enrolls First Patient in the MOTOR Study, a Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathies.

http://reatapharma.com/reata-enrolls-first-patient-in-the-motor-study-a-phase-2-study-of-the-safety-efficacy-and-pharmacodynamics-of-rta-408-in-the-treatment-of-mitochondrial-myopathies/

【Clinical Trial Update】Raxone® (idebenone) for LHON

Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.

http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201506&newsid=1931735&newslang=en

Epigenetic regulation of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects

http://www.nature.com/articles/srep10434